Pirocarbotrat: a new radiopharmaceutical for the treatment of solid tumors--comparative studies in N-nitrosomethylurea-induced rat mammary tumors.
Nucl Med Biol
; 24(6): 559-64, 1997 Aug.
Article
em En
| MEDLINE
| ID: mdl-9316085
To evaluate the effectiveness of a single intratumoral dose of Pirocarbotrat, a gelatin-protected charcoal suspension labeled with chromic [32P]pyrophosphate, studies of bioelimination, biodistribution and therapeutic action were carried out in rats, and the results obtained were compared with those of other 32P dispersions. We found that 78.3% of the treated tumors reduced size after 32 days of treatment. At that time, the total eliminated activity was 12.70 +/- 3.90% distributed in urine (8.30 +/- 1.80%) and feces (4.40 +/- 3.50%). Biodistribution studies demonstrate that 84.50 +/- 2.60% of the injected activity remained in the tumor, with no significant concentration in the rest of the organism. We conclude that Pirocarbotrat can be used as a safe agent for brachytherapy of solid tumors with beta particles.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Radioisótopos de Fósforo
/
Partículas beta
/
Braquiterapia
/
Difosfatos
/
Neoplasias Mamárias Experimentais
Limite:
Animals
Idioma:
En
Revista:
Nucl Med Biol
Assunto da revista:
BIOLOGIA
/
MEDICINA NUCLEAR
Ano de publicação:
1997
Tipo de documento:
Article
País de afiliação:
Argentina
País de publicação:
Estados Unidos